Hofseth BioCare ASA: HBC ANNUAL REPORT 2025

27 Mar 2026 17:08 CET

The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial
statements for 2025, and HBC has today published the Annual Report and
Sustainability Report for 2025. In October 2025, the Company announced a
successful placing of new ordinary shares with gross proceeds of NOK 158
million. As of the date of this Annual report, the Company has yet to receive
all share deposits and has therefore not completed the transaction. The primary
cause of the delay is stated to be of a technical and legal nature relating to
the main investor who has repeatedly expressed its intention to swiftly complete
the transaction. The Board therefore expects the transaction to be completed in
Q2 2026. The proceeds of the transaction will materially strengthen the
Company's balance sheet and support ongoing growth momentum.

Please find the Annual Report and ESG Report attached.

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: joo@hofsethbiocare.no

About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health company founded on the core values of
sustainability, optimal utilization of natural resources and full traceability.
It upcycles the side streams of the salmon industry by taking fresh filleted
salmon and converting it from a waste product into ingredients to improve human
and pet health.
These ingredients are ProGo®, a mix of bioactive peptides and collagen, OmeGo®,
a whole salmon oil, with all the fatty acid fractions contained in fish, and
CalGo® / NT-II® salmon bone powder containing calcium hydroxyapatite and
undenatured collagen for bone and joint health.
HBC places scientific evidence at the forefront which has led to important
academic partnerships and the identification of unique health benefits. This
includes the demonstration of improved iron metabolism by boosting the body's
ability to take up and use iron resulting in increased energy and vitality with
ProGo® as well as the activation of the GLP-1 receptor with fat reduction in
overweight adults. OmeGo® has shown important immune health benefits including
recovery from viral infection and improved respiratory health and sleep in
adults troubled by particulate matter pollution. Finally, CalGo® has shown both
bone and joint health benefits to support healthy ageing and active lifestyles.
This work has also resulted in the granting of a number of patents protecting
these discoveries. It has also led to the discovery of potential therapeutics
and HBC has spun out a biotech-focused company, HBC Immunology (HBCI) has raised
external finance, and the lead program is in prostate cancer followed by ovarian
cancer. A separate molecule is targeted as an oral, steroid-sparing therapy for
asthma. HBC's headquarters are in Ålesund, Norway with branches in Oslo, London,
Zürich, New Jersey and Palo Alto.

HBC is listed on Oslo Børs with ticker "HBC".

This information is subject to disclosure requirements pursuant to section 5-12
of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

669694_hofsethbiocareasa-2025-12-31-1-en.zip
669694_Hofseth Biocare 2025 ESG report.pdf
669694_Hofseth Biocare 2025 Annual report.pdf